Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study

Table 2 Non-alcoholic fatty liver disease-associated steatosis stratification accordingly to fatty liver serum biomarkers

	Mild (n = 182)	Moderate/severe (n = 123)	P value1
Fatty liver index	44.65 (26.71-67.91)	74.50 (54.08-88.16)	< 0.001
Hepatic steatosis index	36.66 (33.63-40.89)	41.22 (37.75-45.47)	< 0.001
Atherogenic index	0.35 (0.16-0.50)	0.44 (0.29-0.70)	< 0.001

Data were presented as median (interquartile range).

¹Jonckheere-Terpstra test for trend between categories.